# A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer

> **NCT01586611** · PHASE3 · UNKNOWN · sponsor: **AHS Cancer Control Alberta** · enrollment: 175 (estimated)

## Conditions studied

- Metastatic Pancreas Cancer

## Interventions

- **DRUG:** 5FU, leucovorin, oxaliplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01586611
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-06
- **Primary completion:** 2015-04
- **Final completion:** 2015-06
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2014-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01586611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01586611, "A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01586611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*